Understanding OUR Cytokine-Based Immunotherapy Candidates Our Commitment extends to advancing a robust portfolio of programs geared toward expanding the horizons of cytokine-based immunotherapy, especially for cancers where treatment options remain limited. Make use of the links below to learn a lot more about our portfolio of cytokine-based immunotherapy candidates. https://financefeeds.com/asx-appoints-dirk-mcliesh-as-chief-risk-officer/